Contineum Therapeutics (Contineum Therapeutics) FCF Yield % : -4.54 (As of May. 25, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Contineum Therapeutics's Trailing 12-Month Free Cash Flow is $-18.83 Mil, and Market Cap is $405.40 Mil. Therefore, Contineum Therapeutics's FCF Yield % for today is -4.54%.

The historical rank and industry rank for Contineum Therapeutics's FCF Yield % or its related term are showing as below:

CTNM' s FCF Yield % Range Over the Past 10 Years
Min: -4.77 Med: 0 Max: 0
Current: -4.54

CTNM's FCF Yield % is ranked better than
72.01% of 1554 companies
in the Biotechnology industry
Industry Median: -14.35 vs CTNM: -4.54

Contineum Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

Contineum Therapeutics FCF Yield % Historical Data

The historical data trend for Contineum Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics FCF Yield % Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

FCF Yield %

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Contineum Therapeutics's FCF Yield %

For the Biotechnology subindustry, Contineum Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Contineum Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's FCF Yield % falls into.

Contineum Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Contineum Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	18.935	/	0
	=	N/A%

Contineum Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-8.122	*	4	/	0
	=	N/A%

Contineum Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Contineum Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024